A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)
Phase 3
Completed
- Conditions
- Paget's Disease of Bone
- Registration Number
- NCT00480662
- Lead Sponsor
- Organon and Co
- Brief Summary
To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease
Exclusion Criteria
- Patient cannot stand or sit upright for at least 30 minutes
- Patient has difficulty swallowing or problems with digestive system
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months
- Secondary Outcome Measures
Name Time Method MK0217 will be safely tolerated